Patient-important outcomes in diabetes-time for consensus

Lancet

Volumn 370, Issue 9593, 2007, Pages 1104-1106

  Montori, Victor M ^a   Gandhi, Gunjan Y ^a   Guyatt, Gordon H ^b  

^a Mayo Clinic College of Medicine   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; ROSIGLITAZONE;

ARTICLE; CONSENSUS; GLYCEMIC CONTROL; HUMAN; KIDNEY DISEASE; MORBIDITY; MORTALITY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; RETINOPATHY; RISK;

EID: 34648837457     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61489-5     Document Type: Note

References (11)

1. Guyatt G., Montori V., Devereaux P., Schunemann H., and Bhandari M. Patients at the center: in our practice, and in our use of language. ACP J Club 140 (2004) A11-A12
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
3. Nathan D., Cleary P., Backlund J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
5. University Diabetes Group Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes mellitus II: mortality results. Diabetes 10 suppl 2 (1970) S785-S830
6. Nissen S., Wolski K., and Topol E. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586
7. Nissen S., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
8. Nissen S., Tardif J., Nicholls S., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
9. Montori V., Wang Y., Alonso-Coello P., and Bhagra S. Systematic evaluation of the quality of randomized controlled trials in diabetes. Diabetes Care 29 (2006) 1833-1838
10. Kahn S., Haffner S., Heise M., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
11. Montori V., Gafni A., and Charles C. A shared treatment decision-making approach between patients with chronic conditions and their clinicians: the case of diabetes. Health Expect 9 (2006) 25-36